Barcelona biotech SME offering cloud-based computational enzyme design and protein engineering for biocatalysis, biorefineries, and emerging biomaterial applications.
Zymvol is a Barcelona-based biotech SME specializing in computational enzyme design and protein engineering. They develop cloud-based platforms that use molecular modeling to predict and optimize enzyme behavior, enabling faster and cheaper alternatives to traditional lab-based directed evolution. Their core business sits at the intersection of bioinformatics and industrial biotechnology — helping clients design better enzymes for applications in biorefineries, green chemistry, and biocatalysis. They bridge the gap between academic protein science and industrial enzyme users who need tailored biocatalysts.
Core to ZYMVOLVER (cloud platform for protein editing), UNLOCK-EDD (computer-guided enzyme discovery), B-LigZymes (enzyme structure-function), and SMARTBOX (biocatalytic oxidations).
B-LigZymes focused on lignin valorisation enzymes, SMARTBOX on biocatalytic aromatic modifications, and UNLOCK-EDD on enzyme discovery for industrial applications.
B-LigZymes directly targets bacterial enzymes for lignin biorefinery processes; SMARTBOX addresses aromatic compound biocatalysis relevant to biomass conversion.
BioInspireSensing (2021) explores ion channels, mutagenesis, and bioresorbable materials — a new direction applying protein expertise to biosensor design.
ZYMVOLVER launched a unified cloud platform for protein editing; UNLOCK-EDD built next-generation computer-guided enzyme design tools — both position Zymvol as a software-enabled biotech.
Zymvol started in 2018-2019 firmly rooted in classical enzyme engineering — biocatalysis, directed evolution, lignin valorisation, and biorefinery applications. Their early keywords read like a textbook in industrial enzymology. By 2021, a clear pivot appears: their latest project (BioInspireSensing) moves into biodegradable materials, ion channels, and green electronics — applying their protein modeling capabilities to entirely new domains like implantable biosensors. This suggests they are broadening from pure enzyme design into wider biomolecular engineering.
Zymvol is expanding from industrial enzyme optimization into biomedical and materials applications, suggesting their computational protein modeling platform is becoming a general-purpose tool applicable beyond traditional biocatalysis.
Zymvol operates as both a project leader and a specialized partner. They coordinated 2 of their 5 projects (ZYMVOLVER and UNLOCK-EDD — both centered on their core platform technology), while joining 3 others as a computational modeling contributor. With 24 unique partners across 13 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators. This pattern suggests they are easy to work with and bring a clearly defined, portable contribution — computational enzyme design — that plugs into diverse consortia.
Zymvol has collaborated with 24 unique partners across 13 countries, building an impressively wide network for a company with only 5 projects. Their reach spans well beyond their Iberian base, indicating strong pan-European credibility in computational biology circles.
Zymvol occupies a rare niche: they are a computational biotech SME that packages academic-grade molecular modeling into a usable cloud platform for enzyme design. Unlike university labs that publish papers or large pharma companies with proprietary tools, Zymvol offers accessible, software-driven protein engineering as a service. Their combination of deep bioinformatics expertise with a commercial SaaS model makes them an unusually flexible partner — they can contribute to both fundamental research consortia and industry-driven innovation projects.
